Clinical Trial Update: Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the effect of enzalutamide (MDV3100) on androgen signaling and anti-tumor activity in metastatic castration-resistant prostate cancer, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Progressive Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-11-17